CureVac NV (CVAC)
2.985
+0.04
(+1.53%)
USD |
NASDAQ |
May 07, 16:00
2.985
0.00 (0.00%)
After-Hours: 20:00
CureVac Cash from Investing (TTM): -59.76M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -59.76M |
| September 30, 2023 | -69.92M |
| June 30, 2023 | -80.82M |
| March 31, 2023 | -93.46M |
| December 31, 2022 | -98.60M |
| Date | Value |
|---|---|
| September 30, 2022 | -114.41M |
| June 30, 2022 | -110.12M |
| March 31, 2022 | -126.78M |
| December 31, 2021 | -151.33M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-151.33M
Minimum
Dec 2021
-59.76M
Maximum
Dec 2023
-100.58M
Average
-98.60M
Median
Dec 2022
Cash from Investing (TTM) Benchmarks
| Affimed NV | -39.04M |
| InflaRx NV | -19.16M |
| MorphoSys AG | -- |
| BioNTech SE | -7.529B |
| Immatics NV | -33.98M |